The United States flu vaccine for 2010-2011/AFLURIA® will be manufactured by CSL Laboratories in partnership with Merck Pharmaceuticals. Ingredients: 24.5 mcg of thimerosal mercury (safe level for a 550 pound adult), Neomycin & Polymyxin (antibiotics associated with Kidney Failure, hazardous to fetus), 3 strains of flu virus including A/Brisbane/59/2007 (H1N1 subunits).
CSL/MERCK PARTNERSHIP – Merck & Co., Inc. has entered into an exclusive agreement with CSL Biotherapies, a subsidiary of CSL Limited, to market and distribute AFLURIA® (Influenza Virus Vaccine), CSL’s seasonal influenza (flu) vaccine, in the U.S., for the 2010/2011-2015/2016 flu seasons. With the addition of seasonal flu vaccine, Merck will market eight of the 10 vaccines on the recommended immunization schedule for adults in the U.S.
‘Two flu vaccine makers said on Friday they had started shipping supplies for the U.S. market, one of the earliest starts ever to distributing seasonal influenza vaccine. And U.S. officials said they were changing the labeling on a vaccine made by Australia’s CSL Ltd because it appears to have caused a higher than usual rate of seizures in children.
“The labeling for one vaccine, CSL Limited’s Afluria, has undergone changes this season to inform health care providers about an increased incidence of fever and febrile seizure, which was seen in young children, mainly those younger than 5 years, following administration of the 2010 Southern Hemisphere formulation of CSL’s influenza vaccine,” the U.S. Food and Drug Administration said in a statement.
“CSL Limited will not be supplying the United States with the 0.25 milliliter single-dose, prefilled syringes, which are used in very young children.” The FDA said it was asking CSL to conduct a study of its vaccine in children.
Flu vaccines have to be made fresh every year to match the circulating strains of the virus. They are made using old technology involving chicken eggs, and manufacturers cannot always predict how much vaccine they will be able to produce and when. A few companies can now make vaccine in cells and governments are working with industry to switch over to faster and more predictable ways to make flu vaccines.’
AFLURIA®, Influenza Virus Vaccine for intramuscular injection, is a sterile, clear, colorless to slightly opalescent suspension with some sediment that resuspends upon shaking to form a homogeneous suspension. AFLURIA® is prepared from influenza virus propagated in the allantoic fluid of embryonated chicken eggs. Following harvest, the virus is purified in a sucrose density gradient using a continuous flow zonal centrifuge.
The purified virus is inactivated with beta-propiolactone, and the virus particles are disrupted using sodium taurodeoxycholate to produce a “split virion”. The disrupted virus is further purified and suspended in a phosphate buffered isotonic solution. AFLURIA® is standardized according to USPHS requirements for the 2008-2009 influenza season and is formulated to contain 45 mcg HA per 0.5 mL dose in the recommended ratio of 15 mcg HA for each of the three influenza strains recommended for the 2008-2009 Northern Hemisphere influenza season: A/H1N1 (A/Brisbane/59/2007), A/H3N2 (A/Uruguay/716/2007), and influenza B (B/Florida/4/2006).
A single 0.5 mL dose of AFLURIA® contains sodium chloride (4.1 mg), monobasic sodium phosphate (80 mcg), dibasic sodium phosphate (300 mcg), monobasic potassium phosphate (20 mcg), potassium chloride (20 mcg), and calcium chloride (1.5 mcg). From the manufacturing process, each dose may also contain residual amounts of sodium taurodeoxycholate (≤ 10 ppm), ovalbumin (≤ 1 mcg), neomycin sulfate (≤ 0.2 picograms [pg]), polymyxin B (≤ 0.03 pg), and beta-propiolactone (< 25 nanograms).
• 5 mL multi-dose vial containing ten doses. Thimerosal, a mercury derivative, is added as a preservative; each 0.5 mL dose contains 24.5 mcg of mercury.
WARNINGS AND PRECAUTIONS:
1. Guillain-Barré Syndrome (GBS) – If GBS has occurred within 6 weeks of previous influenza vaccination, the decision to give AFLURIA® should be based on careful consideration of the potential benefits and risks. Neurological disorders temporally associated with influenza vaccination, such as encephalopathy, optic neuritis/neuropathy, partial facial paralysis, and brachial plexus neuropathy, have been reported. Microscopic polyangiitis (vasculitis) has been reported temporally associated with influenza vaccination.
2. AFLURIA® is contraindicated in individuals with known hypersensitivity to eggs or chicken protein, neomycin, or polymyxin, or in anyone who has had a life-threatening reaction to previous influenza vaccination.
3. Serious allergic reactions, including anaphylactic shock, have been observed during postmarketing surveillance in individuals receiving AFLURIA®. Although AFLURIA® contains only a limited quantity of egg protein, this protein can induce immediate hypersensitivity reactions among persons who have severe egg allergy. Allergic reactions include hives, angioedema, allergic asthma, and systemic anaphylaxis.
4. Pregnancy: Animal reproduction studies have not been conducted with AFLURIA®. It is also not known whether AFLURIA® can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. AFLURIA® should be given to a pregnant woman only if clearly needed.
5. Nursing Mothers: AFLURIA® has not been evaluated in nursing mothers. It is not known whether AFLURIA® is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when AFLURIA® is administered to a nursing woman.
6. Pediatric Use: Safety and effectiveness in the pediatric population have not been established.
7. Geriatric Use: In four clinical studies, 343 subjects ages 65 years and older received AFLURIA®. Hemagglutination-inhibiting (HI) antibody responses in geriatric subjects were lower after administration of AFLURIA® in comparison to younger adult subjects (see Clinical Studies ). Adverse event rates were generally similar in frequency to those reported in subjects ages 18 to less than 65 years, although some differences were observed.
VRM: Australian Vaccine Scandal: Most multi-dose vaccines currently average 2.5 micrograms of Thimerosal Mercury. Based on EPA standards this is considered a safe level of exposure for a 250 pound adult. Australia’s 2010 Flu vaccine Panvax contains 50 micrograms of Thimerosal; technically a safe level of exposure for a 5000 pound adult. Unless you were born a Mack Truck this is tantamount to attempted murder. Time for the Australian community to rise up against this tyranny with a massive Class Action law suit.
THE REAL REASON SO MANY YOUNG CHILDREN ARE BEING ADVERSELY AFFECTED BY AUSTRALIA’S 2010 FLU SHOT COCKTAIL (WHICH NOW INCLUDES THE PANVAX VACCINE)?
CONTENTS: A STAGGERING 50 MICROGRAMS OF MERCURY IN THE SHOT (MOST CURRENT MULTI-DOSE VACCINES AVG 2.5), H1N1 SUBUNITS (LIVE VIRUS SLIGHTLY MODIFIED WITH DETERGENT), NEOMYCIN (HAZARDOUS TO ALL PREGNANT WOMEN) & POLYMYXIN (2 ANTIBIOTICS ASSOCIATED WITH KIDNEY FAILURE), BETA-PROPLOLACTONE (CARCINOGEN).
‘Included in the ingredients are two antibiotics, Neomycin and Polymyxin B Sulphate. Both are noted for serious side effects, predominantly kidney failure. It is warned both these antibiotics not be used by pregnant women. Neomycin is in the FDA pregnancy category D. This means that it is known to be harmful to an unborn baby. In the “first tier” of candidates to receive this unregistered, unapproved vaccine, pregnant women are on top of the list. Beta-Propiolactone is another listed ingredient. Ranked as one of the most hazardous compounds (worst 10%) to humans and “reasonably expected to be a human carcinogen” (International Agency for Research on Cancer – IARC, 1999). Βeta-Propiolactone is a disinfectant. Panvax is formulated using chick embryos (Ovalbumin). People who suffer allergy to eggs or anaphylactic reactions may experience problems.’
‘The Australian is reporting that clinical tests were never carried out on this particular vaccine, which was a first-time combination of seasonal flu with Panvax, a vaccine against the H1N1 strain. Australia was the first country to use this type of vaccine, the report said. Panvax was tested on 400 children before its release last year, but the combined shot was not subjected to any clinical trials.’
Related Report: Flu vaccine push already underway; first batch causes seizures in children
VRM Worldwide Autism Study
VRM: The Problem With Vaccines Part 1
VRM: The Problem With Vaccines Part 2 – Synergistic Effect of Heavy Metal Toxicity On The Body
VRM: Vaccine Clinic – A Concise Compendium To The Problem With Vaccines
VRM: The Problem With Vaccines Part 3 – Synthetic Genomics & The Death Of Natural Immunity
VRM: A Concise Compendium To The Problem With Vaccines Part 3 – Synthetic Genomics & The Death Of Natural Immunity
VRM: The Problem With Vaccines Part 4 – Primary Aspects of Vaccine Toxicity Affecting Body
VRM: The Problem With Vaccines Part 5A – Detoxification & Restoration of the Body
VRM: The Problem With Vaccines Part 5B – Detoxification & Restoration of the Body
VRM: Vaccine Ingredients
VRM: Family Charts Gradual Decline Of Daughter
VRM: Autism – Steps To Take Toward Prevention
VRM: Health Matters Part 1
VRM: Health Matters Part 2
VRM: Alternative Cancer Cures That Work
VRM: Pregnancy Tips
VRM: The Vanishing Sperm Count
VRM: Media Spin & Swine Flu Hysteria
VRM: H1N1 Vaccine Surplus From 2009 Reveals Growing Distrust of Gov’t & WHO – Cost To Taxpayers Exceeds 2.5 Billion
VRM: Flu Death Statistics – WHO & The Big Lie
VRM: Canada’s 2010-11 Flu Vaccine A Deadly Concoction
VRM: Australian Vaccine Scandal
VRM: Polio – United Nations & The Great Cull
VRM : Vaccine Industry Deception, Propaganda & Media Collusion
VRM: Birth of Medical & Scientific Dictatorship – Future Scenarios
VRM: H1N1 Bio-weaponry Incorporated
VRM : Aids & The WHO Connection – Criminal Intent
VRM: Morgellons Syndrome & Chemtrails
VRM : Council On Foreign Relations 10/16/09- Major Influence on Government Vaccine Policy
VRM: Closed Door CDC Meeting Reveals Industry Cover-up Of Heavy Metal Toxicity In Vaccines
VRM: The Rockefeller Foundation Drafts A Post-Pandemic Scenario
VRM : World Health Organization & Vaccine Manufacturers Implicated In Massive H1N1 Financial Scam Involving Kickbacks & Cover-ups
VRM : Former Pharmaceutical Representative Gwen Olsen Exposes Systemic Industry Fraud
VRM: Britain’s National Health Service – Criminal Syndicate Swindling Billions While Rapidly Destroying Health Care System
VRM: UK Institutes Brand of Medical Martial Law With ‘Super-Vaccination’ Day
VRM : The Awakening Has Begun
VRM: Medical Martial Law In The US – Sleeping Giant Of Tyranny
VRM : Multi-Virus Vaccine Quinvaxem Proving Deadly
VRM: New Generation Cancer Vaccine Will Cause Infertility
VRM: CDC-Gate Exposes A Trail of Fraud Behind Autism Studies
VRM : Squaline – The Military Agenda Comes Home
VRM Live – 01/28/11: Vaccine Resistance Movement founder Joel Lord discusses Synthetic Genomics, cloned cell vaccine technology & the death of natural immunity, gutter journalism & Dr. Wakefield’s imminent vindication with ‘Truth to Power’ host Paul Mabelis.
VRM Live – 11/04/10: Vaccine Resistance Movement founder Joel Lord lays out the whole vaccine process with Paul Mabelis; including heavy metal toxicity, synergy, pregnancy issues & the basic principles of natural health at risk.
VRM Live – 09/24/10: Vaccine Resistance Movement Founder Joel Lord & activist/radio host Jesse Calhoun lay it all out tonite. Topics include the VRM Worldwide Autism Study, Scientific/Medical dictatorship, Natural Rights & Vaccine Industry fraud exposed. Special thanks to host Paul Mabelis.
If you appreciate the efforts to bring this information forward do consider making a donation. Any amount, no matter how small will help enable me to carry on this invaluable research. See Paypal link on the VRM website (click on ‘Donate’ tab in upper right corner). Thank you all.